UCF 101

• CAT Number: I012039
• CAS Number: 313649-08-0
• Molecular Formula: C27H19N3O5S
• Molecular Weight: 497.52
• Purity: ≥95%
• Target: Serine Protease
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: 5-[[5-[2-(dihydroxyamino)phenyl]furan-2-yl]methylidene]-1,3-diphenyl-2-sulfanylidene-1,3-diazinane-4,6-dione
• InChI: InChI=1S/C27H19N3O5S/c31-25-22(17-20-15-16-24(35-20)21-13-7-8-14-23(21)30(33)34)26(32)29(19-11-5-2-6-12-19)27(36)28(25)18-9-3-1-4-10-18/h1-17,33-34H
• InChIKey: QMGXAGWZCHDZRG-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)N2C(=O)C(=CC3=CC=C(O3)C4=CC=CC=C4N(O)O)C(=O)N(C2=S)C5=CC=CC=C5

UCF-101 (Cat No.:I012039) is a powerful inhibitor of the pro-apoptotic mitochondrial serine protease Omi/HtrA2. It exhibits potent, specific, competitive, and reversible inhibition with an IC50 value of 9.5 μM for His-Omi134-458. This compound demonstrates minimal activity against a range of other tested serine proteases, with IC50 values of ≥200 μM. UCF-101’s selective inhibition of Omi/HtrA2 makes it a valuable tool for studying the role of this protease in apoptotic pathways and potential therapeutic interventions aimed at modulating its activity.

Reference

1: Su D, Ma J, Zhang Z, Tian Y, Shen B. Protective Effects of UCF-101 on Cerebral
Ischemia-Reperfusion (CIR) is Depended on the MAPK/p38/ERK Signaling Pathway.
Cell Mol Neurobiol. 2016 Aug;36(6):907-14. doi: 10.1007/s10571-015-0275-6. Epub
2015 Oct 1. PubMed PMID: 26429193.

2: Reigada D, Nieto-Díaz M, Navarro-Ruiz R, Caballero-López MJ, Del águila A,
Muñoz-Galdeano T, Maza RM. Acute administration of ucf-101 ameliorates the
locomotor impairments induced by a traumatic spinal cord injury. Neuroscience.
2015 Aug 6;300:404-17. doi: 10.1016/j.neuroscience.2015.05.036. Epub 2015 May 22.
PubMed PMID: 26004679.

3: Hu Y, Huang M, Wang P, Xu Q, Zhang B. Ucf-101 protects against cerebral
oxidative injury and cognitive impairment in septic rat. Int Immunopharmacol.
2013 May;16(1):108-13. doi: 10.1016/j.intimp.2013.03.019. Epub 2013 Apr 2. PubMed
PMID: 23557966.

4: Hua B, Dong WB, Li QP, Feng ZQ, Yu H, Zhai XS, Lei XP. [Effects of Ucf-101 on
expression of Omi/HtrA2 in kidneys of postasphyxial neonatal rats]. Zhongguo Dang
Dai Er Ke Za Zhi. 2010 Aug;12(8):658-61. Chinese. PubMed PMID: 20704803.

5: Li Q, Li J, Ren J. UCF-101 mitigates streptozotocin-induced cardiomyocyte
dysfunction: role of AMPK. Am J Physiol Endocrinol Metab. 2009
Oct;297(4):E965-73. doi: 10.1152/ajpendo.00323.2009. Epub 2009 Aug 18. PubMed
PMID: 19690068; PubMed Central PMCID: PMC2763789.

6: Li Q, Hueckstaedt LK, Ren J. The protease inhibitor UCF-101 ameliorates
streptozotocin-induced mouse cardiomyocyte contractile dysfunction in vitro: role
of AMP-activated protein kinase. Exp Physiol. 2009 Sep;94(9):984-94. doi:
10.1113/expphysiol.2009.049189. Epub 2009 Jun 26. Erratum in: Exp Physiol. 2016
Mar 1;101(3):451. PubMed PMID: 19561140; PubMed Central PMCID: PMC2864042.

7: Su D, Su Z, Wang J, Yang S, Ma J. UCF-101, a novel Omi/HtrA2 inhibitor,
protects against cerebral ischemia/reperfusion injury in rats. Anat Rec
(Hoboken). 2009 Jun;292(6):854-61. doi: 10.1002/ar.20910. PubMed PMID: 19462455.

8: Klupsch K, Downward J. The protease inhibitor Ucf-101 induces cellular
responses independently of its known target, HtrA2/Omi. Cell Death Differ. 2006
Dec;13(12):2157-9. Epub 2006 May 12. PubMed PMID: 16691211.